OTCPK:TSTI.F

Stock Analysis Report

Executive Summary

TSO3 Inc. engages in the research, development, production, maintenance, sale, and licensing of sterilization processes, related consumable supplies, and accessories for heat and moisture sensitive medical devices worldwide.

Snowflake

Fundamentals

Limited growth with worrying balance sheet.

Risks

  • TSO3 has significant price volatility in the past 3 months.
  • TSO3 is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has TSO3's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.0%

TSTI.F

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

-34.7%

TSTI.F

9.9%

US Medical Equipment

0.7%

US Market

TSTI.F underperformed the Medical Equipment industry which returned 9.9% over the past year.

TSTI.F underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

TSTI.FIndustryMarket
7 Day-3.0%1.1%-0.6%
30 Day-4.0%1.3%2.9%
90 Day8.5%3.0%1.3%
1 Year-34.7%-34.7%10.8%9.9%2.9%0.7%
3 Year-87.7%-87.7%70.1%64.9%44.6%35.2%
5 Year-67.9%-67.9%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is TSO3's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is TSO3 undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether TSO3 is trading at an attractive price based on the cash flow it is expected to produce in the future. But as TSO3 has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of TSTI.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through TSO3 regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is TSO3 expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

48.0%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

TSO3's revenue is expected to grow significantly at over 20% yearly.

Unable to determine if TSO3 is high growth as no earnings estimate data is available.

TSO3's revenue growth is expected to exceed the United States of America market average.

Unable to compare TSO3's earnings growth to the United States of America market average as no estimate data is available.

Unable to compare TSO3's earnings growth to the low risk savings rate as no estimate data is available.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if TSO3 will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has TSO3 performed over the past 5 years?

-22.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

TSO3 does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare TSO3's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare TSO3's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if TSO3 has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if TSO3 has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if TSO3 improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is TSO3's financial position?


Financial Position Analysis

TSO3 is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

TSO3's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

TSO3 has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if TSO3's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

TSO3 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

TSO3 has less than a year of cash runway based on current free cash flow.

TSO3 has less than a year of cash runway if free cash flow continues to grow at historical rates of 72.2% each year.


Next Steps

Dividend

What is TSO3's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate TSO3's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate TSO3's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as TSO3 has not reported any payouts.

Unable to verify if TSO3's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as TSO3 has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of TSO3's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average management tenure


CEO

Ric Rumble (60yo)

10.9yrs

Tenure

US$427,333

Compensation

Mr. Richard M. Rumble, also known as Ric, serves as a Portfolio Manager at Mariner Investment Group,LLC. Mr. Rumble manages a global emerging market equity portfolio and has experience in emerging market e ...


CEO Compensation Analysis

Ric's remuneration is about average for companies of similar size in United States of America.

Ric's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.1yrs

Average Tenure

The tenure for the TSO3 management team is about average.


Board Age and Tenure

7.4yrs

Average Tenure

66yo

Average Age

The tenure for the TSO3 board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Ric Rumble (60yo)

    President

    • Tenure: 10.9yrs
    • Compensation: US$427.33k
  • Glen Kayll (50yo)

    Chief Financial Officer

    • Tenure: 3.8yrs
    • Compensation: US$251.57k
  • Anan Natarajan

    Senior Vice President of Global Commercialization

    • Tenure: 2.8yrs
    • Compensation: US$476.19k
  • Harold Tessman

    Head of Supply Chain

    • Tenure: 0yrs
    • Compensation: US$243.70k
  • James Mills

    Vice President of Human Resources

    • Tenure: 3.1yrs
    • Compensation: US$783.03k
  • Bradley Catalone

    Chief Scientific Officer

    • Tenure: 2yrs
    • Compensation: US$242.79k
  • Cindy Clark

    Head of Business Development & Administration

    • Tenure: 0yrs
    • Compensation: US$235.00k

Board Members

  • Steve West (66yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$101.98k
  • Linda Rosenstock (68yo)

    Chairperson of the Board

    • Tenure: 1.3yrs
    • Compensation: US$135.64k
  • Richard Marchand

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Bernard Legube

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Charles Hancock

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Paul Malchesky (72yo)

    Member of the Scientific Advisory Board

    • Tenure: 14.3yrs
  • Sara Elford (49yo)

    Independent Director

    • Tenure: 0.4yrs
  • Ric Rumble (60yo)

    President

    • Tenure: 10.9yrs
    • Compensation: US$427.33k
  • Gregg Mosley

    Member of the Scientific Advisory Board

    • Tenure: 13.7yrs
  • James Husman

    Chairman of The Scientific Advisory Board and Member of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: US$4.63k

Company Information

TSO3 Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TSO3 Inc.
  • Ticker: TSTI.F
  • Exchange: OTCPK
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$38.392m
  • Listing Market Cap: CA$28.949m
  • Shares outstanding: 93.64m
  • Website: https://www.tso3.com

Number of Employees


Location

  • TSO3 Inc.
  • 2505, Avenue Dalton
  • Quebec
  • Quebec
  • G1P 3S5
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TOSTSX (The Toronto Stock Exchange)YesCommon SharesCACADAug 2001
TS9DB (Deutsche Boerse AG)YesCommon SharesDEEURAug 2001
TSTI.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDAug 2001

Biography

TSO3 Inc. engages in the research, development, production, maintenance, sale, and licensing of sterilization processes, related consumable supplies, and accessories for heat and moisture sensitive medical ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:19
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.